Compare JBSS & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBSS | CGEM |
|---|---|---|
| Founded | 1959 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 839.3M | 671.7M |
| IPO Year | 1991 | 2021 |
| Metric | JBSS | CGEM |
|---|---|---|
| Price | $72.68 | $12.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $109.00 | $28.00 |
| AVG Volume (30 Days) | 54.8K | ★ 1.3M |
| Earning Date | 01-28-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.43% | N/A |
| EPS Growth | ★ 21.12 | N/A |
| EPS | ★ 5.62 | N/A |
| Revenue | ★ $1,129,733,000.00 | N/A |
| Revenue This Year | $5.40 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.97 | ★ N/A |
| Revenue Growth | ★ 1.88 | N/A |
| 52 Week Low | $58.47 | $5.68 |
| 52 Week High | $91.98 | $13.60 |
| Indicator | JBSS | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 65.13 | 67.30 |
| Support Level | $71.06 | $10.01 |
| Resistance Level | $73.15 | $13.33 |
| Average True Range (ATR) | 1.55 | 1.21 |
| MACD | -0.08 | 0.12 |
| Stochastic Oscillator | 80.46 | 81.18 |
John B Sanfilippo & Son Inc is one of the processors and distributors of peanuts, pecans, cashews, walnuts, almonds, and other nuts in the United States. These nuts are sold under a variety of private brands and the Fisher, Orchard Valley Harvest, and Sunshine Country brand names. It also markets and distributes, and in the majority of cases, manufactures or processes, a diverse product line of food and snack products, including peanut butter, almond butter, cashew butter, candy and confections, snacks and trail mixes, snack bites, sunflower kernels, dried fruit, corn snacks, sesame sticks and other sesame snack products under private brands and brand names.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.